Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel genotype-phenotype correlations, differential cerebellar allele-specific methylation, and a common origin of the (ATTTC)n insertion in spinocerebellar ataxia type 37

  • Sanchez-Flores, Marina
  • Corral-Juan, Marc|||0000-0001-9407-7516
  • Gasch-Navalón, Esther|||0000-0003-1605-3951
  • Cirillo, Davide
  • Sanchez, Ivelisse|||0000-0002-7605-5337
  • Matilla-Dueñas, Antoni|||0000-0002-3514-4181
Spinocerebellar ataxia subtype 37 (SCA37) is a rare disease originally identified in ataxia patients from the Iberian Peninsula with a pure cerebellar syndrome. SCA37 patients carry a pathogenic intronic (ATTTC)n repeat insertion flanked by two polymorphic (ATTTT)n repeats in the Disabled-1 (DAB1) gene leading to cerebellar dysregulation. Herein, we determine the precise configuration of the pathogenic 5ʹ(ATTTT)n-(ATTTC)n-3ʹ(ATTTT)n SCA37 alleles by CRISPR-Cas9 and long-read nanopore sequencing, reveal their epigenomic signatures in SCA37 lymphocytes, fibroblasts, and cerebellar samples, and establish new molecular and clinical correlations. The 5ʹ(ATTTT)n-(ATTTC)n-3ʹ(ATTTT)n pathogenic allele configurations revealed repeat instability and differential methylation signatures. Disease age of onset negatively correlated with the (ATTTC)n, and positively correlated with the 3ʹ(ATTTT)n. Geographic origin and gender significantly correlated with age of onset. Furthermore, significant predictive regression models were obtained by machine learning for age of onset and disease evolution by considering gender, the (ATTTC)n, the 3ʹ(ATTTT)n, and seven CpG positions differentially methylated in SCA37 cerebellum. A common 964-kb genomic region spanning the (ATTTC)n insertion was identified in all SCA37 patients analysed from Portugal and Spain, evidencing a common origin of the SCA37 mutation in the Iberian Peninsula originating 859 years ago (95% CI 647-1378). In conclusion, we demonstrate an accurate determination of the size and configuration of the regulatory 5ʹ(ATTTT)n-(ATTTC)n-3ʹ(ATTTT)n repeat tract, avoiding PCR bias amplification using CRISPR/Cas9-enrichment and nanopore long-read sequencing, resulting relevant for accurate genetic diagnosis of SCA37. Moreover, we determine novel significant genotype-phenotype correlations in SCA37 and identify differential cerebellar allele-specific methylation signatures that may underlie DAB1 pathogenic dysregulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

  • Jiménez, Natalia|||0000-0002-7057-0426
  • Garcia de Herreros, Marta
  • Reig, Oscar|||0000-0003-1166-6943
  • Marín Aguilera, Mercedes
  • Aversa, Caterina
  • Ferrer-Mileo, Laura
  • García-Esteve, Samuel|||0000-0002-7680-2048
  • Rodríguez-Carunchio, Leonardo|||0000-0002-7019-554X
  • Trias, Isabel|||0000-0001-9841-4380
  • Font, Albert|||0000-0003-3908-1111
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Cros Costa, Sara|||0000-0001-8279-784X
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Domènech, Montserrat|||0000-0003-3973-0986
  • Figols, Mariona
  • Carles, Joan|||0000-0002-9983-5934
  • Suárez, Cristina|||0000-0002-0502-5528
  • Herrero Rivera, Daniel
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
  • Cívico, Claudia
  • Sala-González, Núria
  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Ribal, María J.|||0000-0001-8142-5382
  • Prat, Aleix|||0000-0003-2377-540X
  • Mellado, Begoña|||0000-0002-8088-5966
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75.7% presented de novo stage IV and 67.9% high-volume disease. TSGlow (19.2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1.8, p = 0.002) and OS (HR 2, p = 0.002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2.2, p = 0.02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0.4, p < 0.001) and OS (HR 0.4, p = 0.001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

  • Cabrero-de las Heras, Sara|||0000-0002-9364-5371
  • Hernández-Yagüe, Xavier|||0000-0002-3742-1218
  • González Valencia, Andrea|||0009-0005-4236-0199
  • Losa, Ferran|||0000-0003-0111-8708
  • Soler, Gemma
  • Bugés, Cristina|||0000-0003-2013-1510
  • Baraibar, Iosune|||0000-0002-3500-9641
  • Esteve, Anna|||0000-0002-1962-971X
  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Ree, Anne Hansen
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Nieva, Maria
  • Musulén, Eva|||0000-0002-9667-6464
  • Meltzer, Sebastian
  • Lobato, Tania
  • Vendrell-Ayats, Carla|||0009-0000-2740-0918
  • Queralt, C|||0000-0001-9875-0173
  • Navarro, Pilar|||0000-0003-4314-4584
  • Montagut Viladot, Clara|||0000-0003-1438-2903
  • Grau-Leal, Ferran|||0000-0003-3072-2250
  • Camacho Martín, David
  • Legido, Raquel
  • Mulet-Margalef, Nuria|||0000-0002-2385-6448
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential association between S100A4 levels and insulin resistance in prepubertal children and adult subjects with clinically severe obesity

  • Taxerås, Siri D.
  • Galán, María|||0000-0002-4758-8388
  • Campderrós, Laura
  • Piquer García, Irene|||0000-0002-6746-3558
  • Pellitero, Silvia|||0000-0002-9510-7251
  • Martínez, Eva
  • Puig, Rocío
  • Lucena, Icíar
  • Tarascó, Jordi|||0000-0001-6820-7946
  • Moreno, Pau|||0000-0002-6652-120X
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Bel, Joan|||0000-0002-3577-6322
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Martínez, María
  • Ramon-Krauel, Marta|||0000-0003-3027-9105
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Lerin, Carles|||0000-0003-0950-4363
  • Sánchez-Infantes, David|||0000-0001-6086-7501
Objectives: S100A4 has been recently identified as an adipokine associated with insulin resistance (IR) in adult subjects with obesity. However, no data about its levels in children with obesity and only a few approaches regarding its potential mechanism of action have been reported. To obtain a deeper understanding of the role of S100A4 in obesity, (a) S100A4 levels were measured in prepubertal children and adult subjects with and without obesity and studied the relationship with IR and (b) the effects of S100A4 in cultured human adipocytes and vascular smooth muscle cells (VSMCs) were determined. Methods: Sixty-five children (50 with obesity, age 9.0 ±1.1 years and 15 normal weight, age 8.4 ±0.8 years) and fifty-nine adults (43 with severe obesity, age 46 ±11 years and 16 normal weight, age 45 ±9 years) were included. Blood from children and adults and adipose tissue samples from adults were obtained and analysed. Human adipocytes and VSMC were incubated with S100A4 to evaluate their response to this adipokine. Results: Circulating S100A4 levels were increased in both children (P =.002) and adults (P <.001) with obesity compared with their normal-weight controls. In subjects with obesity, S100A4 levels were associated with homeostatic model assessment-insulin resistance (HOMA-IR) in adults (βstd =.42, P =.008) but not in children (βstd =.12, P =.356). Human adipocytes were not sensitive to S100A4, while incubation with this adipokine significantly reduced inflammatory markers in VSMC. Conclusions: Our human data demonstrate that higher S100A4 levels are a marker of IR in adults with obesity but not in prepubertal children. Furthermore, the in vitro results suggest that S100A4 might exert an anti-inflammatory effect. Further studies will be necessary to determine whether S100A4 can be a therapeutic target for obesity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.